HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Table and Figures All Versions of this Article: 291/5/L1005    most recent 00174.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Allen, I. C. Articles by Koller, B. H. Search for Related Content PubMed PubMed Citation Articles by Allen, I. C. Articles by Koller, B. H.

Expression and function of NPSR1/GPRA in the lung before and after induction of asthma-like disease

¹Curriculum in Genetics and Molecular Biology, ²Department of Genetics, ³Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and ⁴Department of Biochemistry and Molecular Biology, Merck Frosst Canada Limited, Kirkland, Quebec City, Canada

Submitted 12 May 2006 ; accepted in final form 30 June 2006

A genetic contribution to asthma susceptibility is well recognized, and linkage studies have identified a large number of genes associated with asthma pathogenesis. Recently, a locus encoding a seven-transmembrane protein was shown to be associated with asthma in founder populations. The expression of the protein GPRA (G protein-coupled receptor for asthma susceptibility) in human airway epithelia and smooth muscle, and its increased expression in a mouse model of asthma, suggested that a gain-of-function mutation in this gene increased the disease risk. However, we report here that the development of allergic lung disease in GPRA-deficient mice is unaltered. A possible explanation for this finding became apparent upon reexamination of the expression of this gene. In contrast to initial studies, our analyses failed to detect expression of GPRA in human lung tissue or in mice with allergic lung disease. We identify a single parameter that distinguishes GPRA-deficient and wild-type mice. Whereas the change in airway resistance in response to methacholine was identical in control and GPRA-deficient mice, the mutant animals showed an attenuated response to thromboxane, a cholinergic receptor-dependent bronchoconstricting agent. Together, our studies fail to support a direct contribution of GPRA to asthma pathogenesis. However, our data suggest that GPRA may contribute to the asthmatic phenotype by altering the activity of other pathways, such as neurally mediated mechanisms, that contribute to disease. This interpretation is supported by high levels of GPRA expression in the brain and its recent identification as the neuropeptide S receptor.

neuropeptide S; G protein-coupled receptor; allergic lung disease; anaphylaxis

This article has been cited by other articles:

				V. Camarda, A. Rizzi, C. Ruzza, S. Zucchini, G. Marzola, E. Marzola, R. Guerrini, S. Salvadori, R. K. Reinscheid, D. Regoli, et al. In Vitro and in Vivo Pharmacological Characterization of the Neuropeptide S Receptor Antagonist [D-Cys(tBu)5]Neuropeptide S J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 549 - 555. [Abstract] [Full Text] [PDF]

				N. Okamura, S. A. Habay, J. Zeng, A. R. Chamberlin, and R. K. Reinscheid Synthesis and Pharmacological in Vitro and in Vivo Profile of 3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic Acid 4-Fluoro-benzylamide (SHA 68), a Selective Antagonist of the Neuropeptide S Receptor J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 893 - 901. [Abstract] [Full Text] [PDF]